Role of CYB5A in pancreatic cancer prognosis and autophagy modulation

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Giovannetti, Elisa ^a   Wang, Qiuyan ^f   Avan, Amir ^a   Funel, Niccola ^c   Lagerweij, Tonny ^a   Lee, Jih Hsiang ^f   Caretti, Viola ^a,d   Van Der Velde, Arjan ^b   Boggi, Ugo ^c   Wang, Yisong ^a   Vasile, Enrico ^c   Peters, Godefridus J ^a   Wurdinger, Thomas ^a,e,f   Giaccone, Giuseppe ^f  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF PISA   (Italy)

^d STANFORD UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYB5A PROTEIN; GEMCITABINE; LIPOCORTIN 5; LUCIFERASE; MESSENGER RNA; PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; CYTOCHROME B5;

AGED; ANIMAL TISSUE; ARTICLE; ASSAY; AUTOPHAGY; BIOLUMINESCENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL INVASION; CELL LINE; CELL MIGRATION; ELECTRON MICROSCOPY; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MODULATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; ULTRASOUND; UPREGULATION; WOUND HEALING; CELL MOTION; CELL PROLIFERATION; CHROMOSOME 18; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PREDICTIVE VALUE; PRIMARY CELL CULTURE; PROGNOSIS; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR INVASION;

AUTOPHAGY; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 18; CYTOCHROMES B5; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PRIMARY CELL CULTURE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84892659182     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt346     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607-620.
3. Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res. 2012;18(16):4249-4256.
4. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-1806.
5. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
6. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399- 405.
7. Lee JH, Giovannetti E, Hwang JH, et al. Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Clin Cancer Res. 2012;18(2):524-533.
8. Zhang P, Chan DW, Zhu Y, et al. Identification of carboxypeptidase of glutamate like-B as a candidate suppressor in cell growth and metastasis in human hepatocellular carcinoma. Clin Cancer Res. 2006;12(22):6617-6625.
9. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70(11):4528-4538.
10. Funel N, Vasile E, Del Chiaro M, et al. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Ann Oncol. 2011;22(2):482-484.
11. Martino L, Vasile E, Del Chiaro M, et al. Palmitate activates autophagy in INS-1E ?-cells and in isolated rat and human pancreatic islets. PLoS One. 2012;7(5):e36188.
12. Giovannetti E, Labots M, Dekker H, et al. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des. 2013;19(5):927-939.
13. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258-261.
14. Nepusz T, Yu H, Paccanaro A. Detecting overlapping protein complexes in protein-protein interaction networks. Nat Methods. 2012;9(5):471-472.
15. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21(16):3448-3449.
16. Wurdinger T, Badr C, Pike L, et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods. 2008;5(2):171-173.
17. Avan A, Caretti V, Funel N, et al. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma [published online ahead of print October 1, 2013]. Cancer Res. doi: 10.1158/0008-5472. CAN-13-0837.
18. Xie X, Le L, Fan Y, Lv L, Zhang J. Autophagy is induced through the ROS-TP53-DRAM1 pathway in response to mitochondrial protein synthesis inhibition. Autophagy. 2012;8(7):1071-1084.
19. Melisi D, Xia Q, Paradiso G, et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst. 2011;103(15):1190- 1204.
20. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004;64(22):8420-8427.
21. Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009;137(5):821-834.
22. Ewing RM, Chu P, Elisma F, et al. Large-scale mapping of human proteinprotein interactions by mass spectrometry. Mol Syst Biol. 2007;3:89.
23. Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/?/NF-?B activation by IL-1? and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(1):105-120.
24. Yachida S, Xia Q, Paradiso G, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114- 1117.
25. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226(3):248-257.
26. Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240(2):293-298.
27. Frampton AE, Krell J, Giovannetti E, et al. Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther. 2012;12(10):1275-1278.
28. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012;11(3):201-214.
29. van de Vijver MJ, He YD, van't Veer LJ,et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999- 2009.
30. Winter JM, Tang LH, Klimstra DS, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012;7(7):e40157.
31. Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16(3):259-266.
32. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55(88):2016-2027.
33. Balagurunathan Y, Morse DL, Hostetter G, et al. Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther. 2008;7(9):3071-3080.
34. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003;162(4):1151-1162.
35. Sriram KB, Larsen JE, Savarimuthu Francis SM, et al. Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS One. 2012;7(2):e30398.
36. Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. New Engl J Med. 1986; 314(12):757-761.
37. Kurian JR, Chin NA, Longlais BJ, Hayes KL, Trepanier LA. Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5. Chem Res Toxicol. 2006; 19(10):1366-1373.
38. Ropolo A, Bagnes CI, Molejon MI, et al. Chemotherapy and autophagy-mediated cell death in pancreatic cancer cells. Pancreatology. 2012;12(1):1-7.
39. Kang R, Tang D, Lotze MT, Zeh HJ 3rd. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy. 2012;8(6):989-991.
40. Monma H, Harashima N, Inao T, Okano S, Tajima Y, Harada M. The HSP70 and autophagy inhibitor pifithrin-? enhances the antitumor effects of TRAIL on human pancreatic cancer. Mol Cancer Ther. 2013;12(4):341-351.
41. Pardo R, Lo Ré A, Archange C, et al. Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology. 2010;10(1):19-26.
42. Naumann P, Fortunato F, Zentgraf H, Büchler MW, Herr I, Werner J. Autophagy and cell death signaling following dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. Int J Oncol. 2011;39(1):101-109.
43. Ye H, Arron JR, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature. 2002;418(6896):443-447.
44. Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10(10):1199-1207.
45. Wong BR, Besser D, Kim N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell. 1999;4(6):1041-1049.
46. Kelber JA, Reno T, Kaushal S, et al. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res. 2012;72(10):2554-2564.
47. Bao J, Gur G, Yarden Y. Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci USA. 2003;100(5):2438-2443.
48. Starczynowski DT, Lockwood WW, Deléhouzée S, et al. TRAF6 is an amplified oncogene bridging the RAS and NF-?B pathways in human lung cancer. J Clin Invest. 2011;121(10):4095-4105.
49. Liu H, Tamashiro S, Baritaki S, et al. TRAF6 Activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk. 2012;12(3):155-163.
50. Trauzold A, Röder C, Sipos B, et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J. 2005;19(6):620-622.